IonDX provides next-generation ion mobility technology to analyze biologic drugs from glycoproteins and CRISPR-Cas to mRNA and lipid nanoparticles
Accelerating the next generation of biologic drugs
Soft ionization conditions allow native conformations of biomacromolecules to be studied, e.g., non-covalent protein complexes, high molecular weight aggregates, mRNA, glycoproteins, CRISPR-Cas, virus particles, lipid nanoparticles
IonDX’s patented ion mobility technology provides powerful analytical characterization in a very compact benchtop design.
IMgenius determines the mobility of a population of molecular ions as they travel through a gas under the influence of an electric field. Small ions have higher mobility than larger ions because they experience less drag as they travel through a gas.